These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 15849631)

  • 1. [Lumiracoxib reduces ulcer complications in comparison to NSAR].
    Z Orthop Ihre Grenzgeb; 2005; 143(2):158-9. PubMed ID: 15849631
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial.
    Schnitzer TJ; Burmester GR; Mysler E; Hochberg MC; Doherty M; Ehrsam E; Gitton X; Krammer G; Mellein B; Matchaba P; Gimona A; Hawkey CJ;
    Lancet; 2004 Aug 21-27; 364(9435):665-74. PubMed ID: 15325831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A coxib a day won't keep the doctor away.
    Topol EJ; Falk GW
    Lancet; 2004 Aug 21-27; 364(9435):639-40. PubMed ID: 15325809
    [No Abstract]   [Full Text] [Related]  

  • 4. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial.
    Farkouh ME; Kirshner H; Harrington RA; Ruland S; Verheugt FW; Schnitzer TJ; Burmester GR; Mysler E; Hochberg MC; Doherty M; Ehrsam E; Gitton X; Krammer G; Mellein B; Gimona A; Matchaba P; Hawkey CJ; Chesebro JH;
    Lancet; 2004 Aug 21-27; 364(9435):675-84. PubMed ID: 15325832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic arthritis research and gastrointestinal event trial of lumiracoxib - study design and patient demographics.
    Hawkey CJ; Farkouh M; Gitton X; Ehrsam E; Huels J; Richardson P
    Aliment Pharmacol Ther; 2004 Jul; 20(1):51-63. PubMed ID: 15225171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence in practice--number 3: Cox 2 inhibitors.
    Summerton N
    Br J Gen Pract; 2004 Nov; 54(508):880-1. PubMed ID: 15527623
    [No Abstract]   [Full Text] [Related]  

  • 7. Reduced incidence of gastroduodenal ulcers associated with lumiracoxib compared with ibuprofen in patients with rheumatoid arthritis.
    Kivitz AJ; Nayiager S; Schimansky T; Gimona A; Thurston HJ; Hawkey C
    Aliment Pharmacol Ther; 2004 Jun; 19(11):1189-98. PubMed ID: 15153172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of lumiracoxib compared with NSAIDs.
    Rosenberg JA; Goldstein JL
    Nat Clin Pract Gastroenterol Hepatol; 2005 Jan; 2(1):14-5. PubMed ID: 16265092
    [No Abstract]   [Full Text] [Related]  

  • 9. Gastroduodenal safety and tolerability of lumiracoxib compared with Ibuprofen and celecoxib in patients with osteoarthritis.
    Hawkey CC; Svoboda P; Fiedorowicz-Fabrycy IF; Nasonov EL; Pikhlak EG; Cousin M; Gitton X; Hoexter G
    J Rheumatol; 2004 Sep; 31(9):1804-10. PubMed ID: 15338504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The COX 2 selective inhibitors: what the newspapers have not told you.
    Simon LS
    Bull NYU Hosp Jt Dis; 2007; 65(3):229-41. PubMed ID: 17922675
    [No Abstract]   [Full Text] [Related]  

  • 11. Selective cyclo-oxygenase inhibitors.
    Wilcock M; MacKenzie I
    Lancet; 2001 Aug; 358(9280):510. PubMed ID: 11515521
    [No Abstract]   [Full Text] [Related]  

  • 12. Doubt and certainty about nonsteroidal anti-inflammatory drugs in the year 2000: a multidisciplinary expert statement.
    Hawkey CJ; Lanas AI;
    Am J Med; 2001 Jan; 110(1A):79S-100S. PubMed ID: 11166005
    [No Abstract]   [Full Text] [Related]  

  • 13. Are selective COX 2 inhibitors superior to traditional NSAIDs? Pharmacia's response to editorial.
    Geis GS
    BMJ; 2002 Jul; 325(7356):161; author reply 161. PubMed ID: 12134853
    [No Abstract]   [Full Text] [Related]  

  • 14. [NSAIDs for therapy of rheumatoid arthritis. Introduction].
    Takasaki Y
    Nihon Rinsho; 2005 Jan; 63 Suppl 1():473-6. PubMed ID: 15799402
    [No Abstract]   [Full Text] [Related]  

  • 15. Cardiovascular safety of lumiracoxib: a meta-analysis of all randomized controlled trials > or =1 week and up to 1 year in duration of patients with osteoarthritis and rheumatoid arthritis.
    Matchaba P; Gitton X; Krammer G; Ehrsam E; Sloan VS; Olson M; Mellein B; Hoexter G; Orloff J; Garaud JJ
    Clin Ther; 2005 Aug; 27(8):1196-214. PubMed ID: 16199245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and tolerability of lumiracoxib in the treatment of osteoarthritis of the knee: a 13-week, randomized, double-blind comparison with celecoxib and placebo.
    Sheldon E; Beaulieu A; Paster Z; Dutta D; Yu S; Sloan VS
    Clin Ther; 2005 Jan; 27(1):64-77. PubMed ID: 15763607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Secondary and primary prophylaxis of gastropathy associated with nonsteroidal antiinflammatory drugs or low-dose-aspirin: a review based on four clinical scenarios].
    Limmer S; Ittel TH; Wietholtz H
    Z Gastroenterol; 2003 Aug; 41(8):719-28. PubMed ID: 12910426
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Selective cox-2 inhibitors. Better tolerance than NSAID plus antacid].
    MMW Fortschr Med; 2004 Apr; 146(15):66. PubMed ID: 15373027
    [No Abstract]   [Full Text] [Related]  

  • 19. NSAIDs and aspirin: notorious or FAMOUS?
    Hawkey CJ
    Lancet; 2009 Jul; 374(9684):93-4. PubMed ID: 19577799
    [No Abstract]   [Full Text] [Related]  

  • 20. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
    Laine L; Curtis SP; Cryer B; Kaur A; Cannon CP;
    Lancet; 2007 Feb; 369(9560):465-73. PubMed ID: 17292766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.